Detalhe da pesquisa
1.
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Blood
; 139(5): 686-689, 2022 02 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34788401
2.
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Lancet Oncol
; 22(10): 1391-1402, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34534514
3.
Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care.
Cancers (Basel)
; 16(5)2024 Feb 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38473342
4.
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
Blood Adv
; 8(4): 832-841, 2024 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38163317
5.
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
Leukemia
; 35(4): 1064-1072, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32820271